J
Jeffrey E. Lancet
Researcher at University of South Florida
Publications - 68
Citations - 4619
Jeffrey E. Lancet is an academic researcher from University of South Florida. The author has contributed to research in topics: Myeloid leukemia & Cytarabine. The author has an hindex of 28, co-authored 68 publications receiving 3596 citations. Previous affiliations of Jeffrey E. Lancet include University of Rochester & Moffitt Cancer Center.
Papers
More filters
Journal ArticleDOI
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet,Geoffrey L. Uy,Jorge E. Cortes,Laura F. Newell,Tara L. Lin,Ellen K. Ritchie,Robert K. Stuart,Stephen A. Strickland,Donna E. Hogge,Scott R. Solomon,Richard Stone,Dale L. Bixby,Jonathan E. Kolitz,Gary J. Schiller,Matthew J. Wieduwilt,Daniel H. Ryan,Antje Hoering,Kamalika Banerjee,Michael Chiarella,Arthur C. Louie,Bruno C. Medeiros +20 more
TL;DR: CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML, and improved outcomes were observed across age-groups and AML subtypes.
Journal ArticleDOI
Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology
Margaret R. O'Donnell,Martin S. Tallman,Camille N. Abboud,Jessica K. Altman,Frederick R. Appelbaum,Daniel A. Arber,Vijaya Raj Bhatt,Dale L. Bixby,William Blum,Steven Coutre,Marcos de Lima,Amir T. Fathi,Melanie Fiorella,James M. Foran,Steven D. Gore,Aric C. Hall,Patricia Kropf,Jeffrey E. Lancet,Lori J. Maness,Guido Marcucci,Michael Gary Martin,Joseph O. Moore,Rebecca L. Olin,Deniz Peker,Daniel A. Pollyea,Keith W. Pratz,Farhad Ravandi,Paul J. Shami,Richard Stone,Stephen A. Strickland,Eunice S. Wang,Matthew J. Wieduwilt,Kristina M. Gregory,Ndiya Ogba +33 more
TL;DR: This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger and older adult patients.
Journal ArticleDOI
NCCN Clinical Practice Guidelines Acute myeloid leukemia.
M R O'Donnell,Camille N. Abboud,Jessica K. Altman,F R Appelbaum,Daniel A. Arber,Eyal C. Attar,Uma Borate,S. E. Coutre,Lloyd E. Damon,Salil Goorha,Jeffrey E. Lancet,Lori J. Maness,G. Marcucci,Michael Millenson,Joseph O. Moore,Farhad Ravandi,Paul J. Shami,B D Smith,Richard Stone,Stephen A. Strickland,Martin S. Tallman,Eunice S. Wang,Maoko Naganuma,Kristina M. Gregory +23 more
TL;DR: Challenges in the management of the adult with AML are discussed, including ongoing questions concerning the optimal choice of induction and postremission therapy such as the rationale for and role of allogeneic and autologous stem cell transplantation in a variety of settings, the special considerations pertaining to the older patient, and the development of new, so-called targeted therapies.
Journal ArticleDOI
Acute myeloid leukemia, version 3.2019
Martin S. Tallman,Eunice S. Wang,Jessica K. Altman,Frederick R. Appelbaum,Vijaya Raj Bhatt,Dale L. Bixby,Steven Coutre,Marcos de Lima,Amir T. Fathi,Melanie Fiorella,James M. Foran,Aric C. Hall,Meagan A. Jacoby,Jeffrey E. Lancet,Thomas W. LeBlanc,Gabriel N. Mannis,Guido Marcucci,Michael Gary Martin,Alice S. Mims,Margaret R. O'Donnell,Rebecca L. Olin,Deniz Peker,Alexander E. Perl,Daniel A. Pollyea,Keith W. Pratz,Thomas Prebet,Farhad Ravandi,Paul J. Shami,Richard Stone,Stephen A. Strickland,Matthew J. Wieduwilt,Kristina M. Gregory,Lydia J. Hammond,Ndiya Ogba +33 more
TL;DR: This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger and older adult patients.
Journal ArticleDOI
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Jeffrey E. Lancet,Jorge E. Cortes,Donna E. Hogge,Martin S. Tallman,Tibor Kovacsovics,Lloyd E. Damon,Rami S. Komrokji,Scott R. Solomon,Jonathan E. Kolitz,Maureen Cooper,Andrew M. Yeager,Arthur C. Louie,Eric J. Feldman +12 more
TL;DR: A clinical benefit with CPX-351 is suggested, particularly among patients with secondary acute myeloid leukemia, and the rationale for a phase 3 trial currently underway in newly diagnosed secondary AML patients is provided.